First in vitro lung cancer test launched
A new in vitro lung cancer diagnostic test has been launched by Roche Diagnostics to provide improved detection of cancer.
List view / Grid view
A new in vitro lung cancer diagnostic test has been launched by Roche Diagnostics to provide improved detection of cancer.
The advent of CRISPR/Cas9 gene editing, together with the plummeting cost of whole-genome sequencing, has cleared a path for the development of customised cancer cell models. Here, we discuss recent developments in the field and challenges associated with targeted-therapy resistance.
A new study has found a small molecule which prevents cancer cells from mutating and becoming resistant to chemotherapy.
Scientists have discovered a cell intrinsic tumour suppressor role of the innate immune sensor Toll-like receptor 2.
A new signalling protein discovery could lead to drug-based therapies to treat hyperparathyroidism.
A study has identified a molecule which boosts immune cell function and could be used in cancer therapies.
The SCIB2 vaccine is to to be administered using new nanoparticle formulation in planned Phase 1/2 clinical trial.
The global gene editing tools market is estimated to have accounted for more than US$258 million in terms of value in 2018.
Researchers have discovered an acid-activated protein which could stop damage to tissues as a result of stroke and other health issues.
A new approach to targeting cancer cells that circumvents a challenge faced by currently available cancer drugs has been developed.
A new way to cleanly separate out cancer cells from a blood sample will enable comprehensive genetic profiling of the cancer cells.
By the 1890s William B. Coley had injected streptococcal organisms in patients with solid tumours (“Coley’s Toxins”) to activate the immune system. Coley (1862-1936) was an American bone surgeon and pioneer of cancer immunotherapy. He was convinced that post-surgical infections had helped patients to recover better from their cancer by…
Comprehensive tumour profiling promises new therapeutic options for patients with advanced cancer.
A new technique, called ECCITE-seq, has been developed to allow researchers to perform high-throughput measurements of multiple modalities of information from single cells.
Method IDs which target therapies, inadequately on their own, can be paired up to kill non-responsive cancers...